Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma.

Autor:	Zhou B; Institute of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States., Bekerman VP; Institute of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States., Khouri AS; Institute of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States.
Jazyk:	angličtina
Zdroj:	Journal of current glaucoma practice [J Curr Glaucoma Pract] 2022 Sep-Dec; Vol. 16 (3), pp. 166-169.
DOI:	10.5005/jp-journals-10078-1386
Abstrakt:	Aim: To investigate the long-term efficacy of adjunctive use of latanoprostene bunod (LBN), a new nitric oxide donating prostaglandin medication, in refractory cases of glaucoma at a tertiary care center. Materials and Methods: A review for patients who received add-on LBN was conducted from 1 st January 2018 to 31 st August 2020. A total of 33 patients (53 eyes) met the inclusion criteria of being on ≥3 topical medications, having an intraocular pressure measurement prior to starting LBN, and having adequate follow-up. Baseline demographics, prior treatments, adverse effects, and intraocular pressures measured at baseline, 3, 6, and 12 months were recorded. Results: Mean baseline intraocular pressure (IOP) [mm Hg ± standard deviation (SD)] was 19.9 ± 6.0. At 3 months, 49 eyes had a mean IOP of 17.3 ± 5.5 ( p < 0.01) with an absolute reduction of 2.6 ± 6.6 and a percent reduction of 9 ± 28%. At 6 months, 35 eyes had a mean IOP of 17.2 ± 4.7 ( p < 0.01) with an absolute reduction of 3.6 ± 7.4 and a percent reduction of 11 ± 30%. At 12 months, 28 eyes had a mean IOP of 16 ± 4.5 ( p < 0.01) with an absolute reduction of 5.8 ± 7.4 and a percent reduction of 19 ± 38%. Over the course of the study, 18 eyes were lost to follow-up. Three eyes had a laser trabeculoplasty, and four eyes required incisional surgery. No eyes discontinued the medication due to adverse effects. Conclusion: Adjunctive use of LBN in refractory glaucoma showed clinically and statistically significant IOP reductions at 3, 6, and 12-month time points. IOP reduction in patients was stable throughout the course of the study, with the largest decreases seen at the 12-month interval. Clinical Significance: LBN was well tolerated by patients and may be useful as an additive agent in providing long-term intraocular pressure reduction for patients with severe glaucoma on maximal therapy. How to Cite This Article: Zhou B, Bekerman VP, Khouri AS. Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma. J Curr Glaucoma Pract 2022;16(3):166-169. Competing Interests: Source of support: Nil Conflict of interest: None (Copyright © 2022; The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu